(0.80%) 5 277.51 points
(1.51%) 38 686 points
(-0.01%) 16 735 points
(-0.94%) $77.18
(0.35%) $2.58
(-0.79%) $2 347.70
(-3.10%) $30.56
(0.63%) $1 044.50
(-0.17%) $0.921
(-0.49%) $10.49
(-0.05%) $0.785
(0.15%) $90.40
@ $45.58
Issued: 14 Feb 2024 @ 09:32
Return: -19.81%
Previous signal: Feb 13 - 15:04
Previous signal:
Return: 1.54 %
Live Chart Being Loaded With Signals
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics...
Stats | |
---|---|
Today's Volume | 882 484 |
Average Volume | 728 615 |
Market Cap | 2.77B |
EPS | $0 ( 2024-05-31 ) |
Next earnings date | ( $-0.560 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -18.27 |
ATR14 | $0.0440 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-31 | Rosen Terry J | Buy | 16 200 | Stock Option (right to buy) |
2024-05-31 | Kelley Susan L. | Buy | 16 200 | Stock Option (right to buy) |
2024-05-31 | Hampton Malcolm Garret | Buy | 16 200 | Stock Option (right to buy) |
2024-05-31 | Stein Jeffrey | Buy | 16 200 | Stock Option (right to buy) |
2024-05-31 | Morrison Scott W | Buy | 16 200 | Stock Option (right to buy) |
INSIDER POWER |
---|
21.37 |
Last 100 transactions |
Buy: 1 731 485 | Sell: 1 162 652 |
Volume Correlation
IDEAYA Biosciences Inc Correlation
10 Most Positive Correlations | |
---|---|
MREO | 0.887 |
CPLP | 0.874 |
CFBK | 0.865 |
RBKB | 0.841 |
AVIR | 0.828 |
BHFAP | 0.827 |
BHFAO | 0.819 |
VSTM | 0.817 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
IDEAYA Biosciences Inc Correlation - Currency/Commodity
IDEAYA Biosciences Inc Financials
Annual | 2023 |
Revenue: | $23.39M |
Gross Profit: | $19.38M (82.86 %) |
EPS: | $-1.960 |
FY | 2023 |
Revenue: | $23.39M |
Gross Profit: | $19.38M (82.86 %) |
EPS: | $-1.960 |
FY | 2022 |
Revenue: | $50.93M |
Gross Profit: | $48.83M (95.87 %) |
EPS: | $-1.320 |
FY | 2021 |
Revenue: | $27.94M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.410 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
IDEAYA Biosciences Inc
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators